BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Drug Development

  Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera

  Novartis today reported the final analysis from the NETTER-1 phase III study comparing treatment using Lutathera® (INN: lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) plus 30 mg octreotide LAR to 60 mg of octreotide LAR in patients with midgut neuroendocrine tumors

  June 3, 2021

   · 

  16 min read
• Alkermes to Take Part in the Goldman Sachs Annual Global Healthcare Conference

  Alkermes plc announced that management will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 10:30 a.m. ET.

  June 3, 2021

   · 

  1 min read
• Biotech Beach

  Children’s Hospital Los Angeles Awarded $2 Million to Address Adverse Childhood Experiences

  Children’s Hospital Los Angeles has been awarded a $2 million grant from the state of California to study a precision medicine approach to screening children for adverse childhood experiences.

  June 3, 2021

   · 

  6 min read
• Biotech Bay

  Helix Announces $50 Million Series C Funding to Continue Acceleration into Clinical Population Genomics and COVID-19 Viral Surveillance

  Helix, the leading population genomics and COVID-19 testing company, has closed on its Series C funding round led by existing investors Warburg Pincus, DFJ Growth, Kleiner Perkins Caufield Byers, Mayo Clinic and Temasek

  June 3, 2021

   · 

  3 min read
• Drug Development

  LYNPARZA® (olaparib) Reduced the Risk of Invasive Disease Recurrence or Death by 42% Versus Placebo in Adjuvant Treatment of Patients With Germline BRCA Mutations and High-Risk HER2-Negative Early Breast Cancer in Phase 3 OlympiA Trial

  First Medicine Specifically Targeting BRCA Mutations to Demonstrate Statistically Significant Improvement in Invasive Disease-Free Survival in Adjuvant Setting Following Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

  June 3, 2021

   · 

  25 min read